drugset / Trial / NCT02307695

The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes

NCT02307695

Phase 4 Unknown 184 enrolled Nanjing Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate whether saxagliptin could reduce the fluctuation of glycemia and improve the glycemic control in those type 1 diabetes through mechanisms of suppressing glucagon secretion, improving beta cell function, and re-regulating of the T cell immune system.

Timeline

Start
2014-11
Primary completion
2017-03
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral
Background Insulin Protein / enzyme biologic